

László Gulácsi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6838674/publications.pdf>

Version: 2024-02-01

261
papers

3,905
citations

136740

32
h-index

197535

49
g-index

295
all docs

295
docs citations

295
times ranked

4469
citing authors

#	ARTICLE	IF	CITATIONS
1	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.5	160
2	The economic impact of dementia in Europe in 2008â€”cost estimates from the Eurocode project. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 825-832.	1.3	158
3	Alopecia areata and health-related quality of life: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016, 175, 561-571.	1.4	144
4	The state of the art in European research on reducing social exclusion and stigma related to mental health: A systematic mapping of the literature. <i>European Psychiatry</i> , 2014, 29, 381-389.	0.1	110
5	EQ-5D in Central and Eastern Europe: 2000â€”2015. <i>Quality of Life Research</i> , 2016, 25, 2693-2710.	1.5	103
6	Biosimilars for the management of rheumatoid arthritis: economic considerations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 43-52.	1.3	83
7	Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. <i>European Journal of Health Economics</i> , 2014, 15, 13-25.	1.4	70
8	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144.	1.3	64
9	Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. <i>World Journal of Gastroenterology</i> , 2015, 21, 1728.	1.4	64
10	Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999â€”2003. <i>Osteoporosis International</i> , 2008, 19, 243-249.	1.3	60
11	Adherence to biologic DMARD therapies in rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1367-1378.	1.4	60
12	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. <i>European Journal of Health Economics</i> , 2014, 15, 111-119.	1.4	60
13	Managing COVID-19 within and across health systems: why we need performance intelligence to coordinate a global response. <i>Health Research Policy and Systems</i> , 2020, 18, 80.	1.1	58
14	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020, 23, 1235-1245.	0.1	58
15	Social/economic costs and quality of life in patients with haemophilia in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 53-65.	1.4	53
16	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. <i>Quality of Life Research</i> , 2017, 26, 3409-3419.	1.5	51
17	Psychometric properties of the Hungarian version of the eHealth Literacy Scale. <i>European Journal of Health Economics</i> , 2019, 20, 57-69.	1.4	49
18	Informal payments for healthcare services and short-term effects of the introduction of visit fee on these payments in Hungary. <i>International Journal of Health Planning and Management</i> , 2012, 27, 63-79.	0.7	48

#	ARTICLE	IF	CITATIONS
19	Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. <i>Rheumatology</i> , 2010, 49, 1920-1928.	0.9	47
20	Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 303-309.	0.6	45
21	User fees for public health care services in Hungary: Expectations, experience, and acceptability from the perspectives of different stakeholders. <i>Health Policy</i> , 2011, 102, 255-262.	1.4	44
22	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7.	0.7	44
23	Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 1102-1108.	1.4	42
24	Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. <i>European Journal of Health Economics</i> , 2014, 15, 121-128.	1.4	41
25	Use of biologics for psoriasis in Central and Eastern European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2222-2230.	1.3	41
26	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	1.4	41
27	Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. <i>Quality of Life Research</i> , 2019, 28, 141-152.	1.5	41
28	The Hungarian Care Managing Organization Pilot Program. <i>Value in Health Regional Issues</i> , 2015, 7, 27-33.	0.5	40
29	A detailed analysis of "not relevant" responses on the <scp>DLQI</scp> in psoriasis: potential biases in treatment decisions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 783-790.	1.3	40
30	The implementation of quality management systems in hospitals: a comparison between three countries. <i>BMC Health Services Research</i> , 2006, 6, 50.	0.9	39
31	Budget-Impact Analyses. <i>Pharmacoeconomics</i> , 2009, 27, 807-827.	1.7	38
32	Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. <i>Rheumatology International</i> , 2009, 30, 199-205.	1.5	36
33	Changes in Equity in Out-of-pocket Payments during the Period of Health Care Reforms: Evidence from Hungary. <i>International Journal for Equity in Health</i> , 2012, 11, 36.	1.5	36
34	Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 43-52.	1.4	35
35	Access to biologics in Crohn's disease in ten European countries. <i>World Journal of Gastroenterology</i> , 2017, 23, 6294.	1.4	35
36	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. <i>Current Medicinal Chemistry</i> , 2019, 26, 259-269.	1.2	34

#	ARTICLE	IF	CITATIONS
37	Exploring consumersâ€™ attitudes towards informal patient payments using the combined method of cluster and multinomial regression analysis - the case of Hungary. BMC Health Services Research, 2013, 13, 62.	0.9	33
38	Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. European Journal of Health Economics, 2014, 15, 35-43.	1.4	33
39	Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. PLoS ONE, 2014, 9, e107704.	1.1	31
40	Issues for countries considering introducing the â€œfourth hurdleâ€: The case of Hungary. International Journal of Technology Assessment in Health Care, 2004, 20, 337-341.	0.2	30
41	Costs of dementia in Hungary. Journal of Nutrition, Health and Aging, 2010, 14, 633-639.	1.5	30
42	Treatment preferences of originator versus biosimilar drugs in Crohnâ€™s disease; discrete choice experiment among gastroenterologists. Scandinavian Journal of Gastroenterology, 2016, 51, 22-27.	0.6	30
43	Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. Pain, 2017, 158, 2259-2267.	2.0	30
44	Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. European Journal of Health Economics, 2012, 13, 525-531.	1.4	27
45	Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. European Journal of Health Economics, 2014, 15, 45-52.	1.4	27
46	Validity of the <sc>EQ</sc> â€”D in patients with pemphigus vulgaris and pemphigus foliaceus. British Journal of Dermatology, 2019, 180, 802-809.	1.4	27
47	Costs of rheumatoid arthritis in Hungary. Journal of Rheumatology, 2007, 34, 1437.	1.0	27
48	Hospital Infection Prevention and Control: A Model for Improving the Quality of Hospital Care in Low- and Middle-Income Countries. Infection Control and Hospital Epidemiology, 1998, 19, 125-135.	1.0	26
49	Quality management and patient safety: Survey results from 102 Hungarian hospitals. Health Policy, 2009, 90, 175-180.	1.4	26
50	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. European Journal of Health Economics, 2014, 15, 53-64.	1.4	26
51	Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary. European Journal of Health Economics, 2019, 20, 43-55.	1.4	25
52	DLQIâ€™ scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. British Journal of Dermatology, 2020, 182, 1167-1175.	1.4	25
53	Validity of EQâ€”Dâ€”L, Skindexâ€”16, DLQI and DLQIâ€™ in patients with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2584-2592.	1.3	25
54	History of health technology assessment in Hungary. International Journal of Technology Assessment in Health Care, 2009, 25, 120-126.	0.2	24

#	ARTICLE	IF	CITATIONS
55	Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. <i>Health Expectations</i> , 2014, 17, 696-709.	1.1	24
56	Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2015, 173, 1076-1080.	1.4	24
57	Is the DLQI appropriate for medical decision-making in psoriasis patients?. <i>Archives of Dermatological Research</i> , 2018, 310, 47-55.	1.1	24
58	Cost-of-illness studies in nine Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2019, 20, 155-172.	1.4	23
59	Quality of life in patients with atopic dermatitis. <i>Cutis</i> , 2019, 104, 174-177.	0.4	23
60	Risk-adjusted infection rates in surgery: a model for outcome measurement in hospitals developing new quality improvement programmes. <i>Journal of Hospital Infection</i> , 2000, 44, 43-52.	1.4	22
61	Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. <i>European Journal of Health Economics</i> , 2014, 15, 101-109.	1.4	22
62	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	0.7	22
63	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. <i>European Journal of Health Economics</i> , 2019, 20, 5-16.	1.4	22
64	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1398-1405.	1.3	21
65	Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 942-943.	0.5	21
66	Patients' Preferences for Healthcare System Reforms in Hungary. <i>Applied Health Economics and Health Policy</i> , 2006, 5, 189-198.	1.0	20
67	Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. <i>European Journal of Health Economics</i> , 2014, 15, 83-92.	1.4	20
68	Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries. <i>Health Policy</i> , 2018, 122, 230-236.	1.4	20
69	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	1.6	20
70	From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries. <i>Social Science and Medicine</i> , 2016, 166, 205-213.	1.8	19
71	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	0.7	19
72	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e267-e269.	1.3	19

#	ARTICLE	IF	CITATIONS
73	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.3	19
74	Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey. <i>Archives of Iranian Medicine</i> , 2015, 18, 153-9.	0.2	19
75	The disease burden of colorectal cancer in Hungary. <i>European Journal of Health Economics</i> , 2010, 10, 35-40.	1.4	18
76	Pricing and reimbursement of drugs and medical devices in Hungary. <i>European Journal of Health Economics</i> , 2002, 3, 271-278.	1.4	17
77	Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. <i>Pathology and Oncology Research</i> , 2015, 21, 619-627.	0.9	17
78	Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs. <i>BMC Geriatrics</i> , 2017, 17, 233.	1.1	17
79	Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey. <i>European Journal of Health Economics</i> , 2019, 20, 71-78.	1.4	17
80	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. <i>European Journal of Health Economics</i> , 2019, 20, 119-132.	1.4	17
81	Outcomes of Digital Biomarker-Based Interventions: Protocol for a Systematic Review of Systematic Reviews. <i>JMIR Research Protocols</i> , 2021, 10, e28204.	0.5	17
82	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013.	2.1	17
83	Discrepancies between the Dermatology Life Quality Index and utility scores. <i>Quality of Life Research</i> , 2016, 25, 1687-1696.	1.5	16
84	The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience. <i>European Journal of Health Economics</i> , 2007, 8, 83-88.	1.4	15
85	Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. <i>British Journal of Dermatology</i> , 2016, 175, 593-599.	1.4	15
86	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 139-147.	0.7	15
87	Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 27-34.	1.4	14
88	The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6770-6778.	0.9	14
89	The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study. <i>European Journal of Health Economics</i> , 2014, 15, 853-867.	1.4	13
90	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. <i>Quality of Life Research</i> , 2020, 29, 2863-2874.	1.5	13

#	ARTICLE	IF	CITATIONS
91	Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 399-408.	0.7	13
92	Hospital Infection Prevention and Control: A Model for Improving the Quality of Hospital Care in Low- and Middle-Income Countries. <i>Infection Control and Hospital Epidemiology</i> , 1998, 19, 125-135.	1.0	13
93	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. <i>European Journal of Health Economics</i> , 2014, 15, 73-82.	1.4	12
94	Health state utilities for migraine based on attack frequency: a time trade-off study. <i>Neurological Sciences</i> , 2015, 36, 197-202.	0.9	12
95	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. <i>European Journal of Health Economics</i> , 2019, 20, 141-154.	1.4	12
96	Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 399-400.	0.6	11
97	Cost of illness of medically treated benign prostatic hyperplasia in Hungary. <i>International Urology and Nephrology</i> , 2015, 47, 1241-1249.	0.6	11
98	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. <i>Value in Health Regional Issues</i> , 2016, 10, 85-90.	0.5	11
99	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 17-30.	1.4	11
100	Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries. <i>European Journal of Health Economics</i> , 2016, 17, 791-799.	1.4	10
101	Patient experiences with outpatient care in Hungary: results of an online population survey. <i>European Journal of Health Economics</i> , 2019, 20, 79-90.	1.4	10
102	Health Economic Publications From the Middle East and North Africa Region: A Scoping Review of the Volume and Methods of Research. <i>Global Journal on Quality and Safety in Healthcare</i> , 2020, 3, 44-54.	0.1	10
103	Comparing cost-sharing practices for pharmaceuticals and health care services among four central European countries. <i>Society and Economy</i> , 2012, 34, 221-240.	0.2	9
104	Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 1-4.	1.4	9
105	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	1.5	9
106	Disease burden of patients with pemphigus from a societal perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 77-86.	0.7	9
107	Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability. <i>Pharmacoeconomics</i> , 2022, 40, 587-599.	1.7	9
108	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117.	1.4	8

#	ARTICLE	IF	CITATIONS
109	Did You Get What You Wanted? Patient Satisfaction and Congruence Between Preferred and Perceived Roles in Medical Decision Making in a Hungarian National Survey. <i>Value in Health Regional Issues</i> , 2020, 22, 61-67.	0.5	8
110	Predicting Patient-Level 3-Level Version of EQ-5D Index Scores From a Large International Database Using Machine Learning and Regression Methods. <i>Value in Health</i> , 2022, 25, 1590-1601.	0.1	8
111	Preferences of Hungarian consumers for quality, access and price attributes of health care services – result of a discrete choice experiment. <i>Society and Economy</i> , 2012, 34, 293-311.	0.2	7
112	HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain. <i>European Journal of Health Economics</i> , 2014, 15, 675-680.	1.4	7
113	Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2106-2113.	1.3	7
114	Subjective well-being in patients with pemphigus: a path analysis. <i>European Journal of Health Economics</i> , 2019, 20, 101-107.	1.4	7
115	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Na ⁺ ve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	1.3	7
116	Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e484-e486.	1.3	7
117	Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above. <i>European Journal of Health Economics</i> , 2022, 23, 1341-1355.	1.4	7
118	Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. <i>Medical Science Monitor</i> , 2010, 16, SR1-5.	0.5	7
119	Health status and costs of ambulatory patients with multiple sclerosis in Hungary. <i>Ideggyogyaszati Szemle</i> , 2012, 65, 316-24.	0.4	7
120	Future challenges for health economics and health technology assessment of biological drugs. <i>European Journal of Health Economics</i> , 2010, 11, 235-238.	1.4	6
121	Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS. <i>European Journal of Health Economics</i> , 2019, 20, 31-41.	1.4	6
122	Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643.	1.7	6
123	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	1.5	6
124	Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs. <i>Value in Health</i> , 2021, 24, 1845-1852.	0.1	6
125	Long-term costs and survival of prostate cancer: a population-based study. <i>International Urology and Nephrology</i> , 2017, 49, 1707-1714.	0.6	5
126	Patient and general population values for luminal and perianal fistulising Crohn's disease health states. <i>European Journal of Health Economics</i> , 2019, 20, 91-100.	1.4	5

#	ARTICLE	IF	CITATIONS
127	Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology. <i>European Journal of Health Economics</i> , 2022, 23, 1243-1255.	1.4	5
128	Health Related Quality of Life of Patients and Their Caregivers In Rare Diseases Results of the Burqol-Rd Project In Hungary. <i>Value in Health</i> , 2014, 17, A538.	0.1	4
129	Does the Implementation of Official User Charges Help to Eradicate Informal Payments â€œ Lessons to be Learnt from the Hungarian Experience. <i>Frontiers in Public Health</i> , 2015, 3, 181.	1.3	4
130	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	1.4	4
131	Eliciting preferences for outpatient care experiences in Hungary: A discrete choice experiment with a national representative sample. <i>PLoS ONE</i> , 2020, 15, e0235165.	1.1	4
132	Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50â€œ70: a cross-sectional study on a representative sample of the Hungarian general population. <i>European Journal of Health Economics</i> , 2021, 22, 1453-1466.	1.4	4
133	Understanding the use of patient-reported data by health care insurers: A scoping review. <i>PLoS ONE</i> , 2020, 15, e0244546.	1.1	4
134	PAR17 BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID ARTHRITIS IN HUNGARY. <i>Value in Health</i> , 2005, 8, A29.	0.1	3
135	Colorectal cancer screening policy in Hungary. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 109-110.	0.2	3
136	Comparing self-perceived and estimated fracture risk by FRAXÂ® of women with osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 4.	1.0	3
137	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	1.0	3
138	Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2213.	1.2	3
139	Nem diabeteses perifÃ©riÃ©s neuropathiÃ©s betegek Ã©letminÃ©sÃ©gÃ©nek mÃ©rÃ©se magyarorszÃ©gi hÃ©ziorvosi praxisokban vÃ©gzett keresztmetszeti vizsgÃ©lat eredmÃ©nyei alapjÃ©n. <i>Ideggyogyaszati Szemle</i> , 2015, 68, 325-330.	0.4	3
140	PHP64 THE EFFECT OF THE PERFORMANCE VOLUME LIMIT (PVL) ON THE DRG FINANCING OF THE HUNGARIAN HOSPITALS. <i>Value in Health</i> , 2008, 11, A48.	0.1	2
141	Budget Impact Analysis Of Biosimilar Rituximab (CT-P10) For The Treatment Of Diffuse Large B-Cell And Follicular Lymphoma In The 28 EU Member States. <i>Value in Health</i> , 2017, 20, A548.	0.1	2
142	PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY. <i>Value in Health</i> , 2019, 22, S794.	0.1	2
143	Subjective expectations regarding longevity and future health: a crossâ€œsectional survey among patients with Crohn's disease. <i>Colorectal Disease</i> , 2021, 23, 105-113.	0.7	2
144	PNS32 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Productivity Loss Costs Reported in Health Economic Publications between 1989-2019. <i>Value in Health</i> , 2020, 23, S649.	0.1	2

#	ARTICLE	IF	CITATIONS
145	Implementation of Country-Wide Pharmacoeconomic Principles in Cancer Care in Developing Countries: Expert-Based Recommendations. <i>Global Journal on Quality and Safety in Healthcare</i> , 2019, 2, 109-114.	0.1	2
146	Patient experiences in a public primary health care clinic: A South African case study. <i>Society and Economy</i> , 2020, 42, 333-347.	0.2	2
147	QUALITY OF LIFE OF PATIENTS WITH NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN; RESULTS FROM A CROSS-SECTIONAL SURVEY IN GENERAL PRACTICES IN HUNGARY. <i>Ideggyogyaszati Szemle</i> , 2015, 68, 325-30.	0.4	2
148	Comparing actuarial and subjective healthy life expectancy estimates: A cross-sectional survey among the general population in Hungary. <i>PLoS ONE</i> , 2022, 17, e0264708.	1.1	2
149	PCN39 GAP BETWEEN INPATIENT TREATMENT COST OF AND MORTALITY DUE TO BREAST CANCER IN HUNGARY. <i>Value in Health</i> , 2007, 10, A135.	0.1	1
150	PCV103 THE PATIENT SAFETY STANDARDS OF ACUTE STROKE MANAGEMENT IN HUNGARY. <i>Value in Health</i> , 2008, 11, A217.	0.1	1
151	PDB66 PAYING FOR COSTLY PHARMACEUTICALSâ€”REIMBURSEMENT STATUS OF LONG-ACTING INSULIN ANALOGUES IN SELECTED DEVELOPED COUNTRIES. <i>Value in Health</i> , 2009, 12, A414.	0.1	1
152	Prioritization Preferences among General Practitioners in Hungary. <i>East European Politics and Societies</i> , 2012, 26, 20-32.	0.7	1
153	Fidaxomicin Therapy for Patients with Clostridium Difficile Infection: A Systematic Literature Review and Meta-Analysis. <i>Value in Health</i> , 2014, 17, A665.	0.1	1
154	Social Utility Values for Pemphigus Vulgaris and Foliaceus: A Composite Time Trade-Off Study. <i>Value in Health</i> , 2015, 18, A673.	0.1	1
155	Time Trade-Off Utility Values in Mild and Severe Primary Dysmenorrhea. <i>Value in Health</i> , 2015, 18, A738-A739.	0.1	1
156	The impact of the recession on health care expenditure â€” How does the Czech Republic, Hungary, Poland and Slovakia compare to other OECD countries?. <i>Society and Economy</i> , 2015, 37, 73-88.	0.2	1
157	A Cost-Effectiveness Analysis of Biosimilar Infliximab (InflectraÂ®) For The Treatment of Psoriatic Arthritis In Nine European Countries. <i>Value in Health</i> , 2016, 19, A540-A541.	0.1	1
158	EQ-5D Studies in Rheumatology in Eight Central and Eastern European Countries. <i>Value in Health</i> , 2016, 19, A542.	0.1	1
159	Construct Validity Of The 10-Year Time Trade-Off Method In Psoriasis Patients. <i>Value in Health</i> , 2016, 19, A571.	0.1	1
160	PMS3 - INFLIXIMAB FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUG-NAIVE RHEUMATOID ARTHRITIS PATIENTS: SYSTEMATIC REVIEW AND DESCRIPTIVE ANALYSIS OF PUBLICATIONS OF RANDOMIZED CONTROLLED TRIALS. <i>Value in Health</i> , 2018, 21, S288.	0.1	1
161	PMU90 - HEALTH PROBLEMS IN HUNGARIAN ELDERLY OUTPATIENTS MEASURED BY THE EQ-5D-3L: COMPARISON WITH A POPULATION NORM FOR CENTRAL EASTERN EUROPE. <i>Value in Health</i> , 2018, 21, S323.	0.1	1
162	PNS401 THE FIRST PARALLEL EQ-5D-3L AND EQ-5D-5L COMPOSITE TIME TRADE-OFF VALUATION STUDY IN EUROPE. <i>Value in Health</i> , 2019, 22, S833.	0.1	1

#	ARTICLE	IF	CITATIONS
163	PNS331 QUANTIFYING THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES USING THE EQ-5D-3L INSTRUMENT. Value in Health, 2019, 22, S820.	0.1	1
164	PNS397 PATIENTS' PERCEPTION OF THE QUALITY OF CONSULTATIONS MODELLED BY PATIENT-REPORTED EXPERIENCE AND HEALTH-RELATED QUALITY OF LIFE MEASURES. Value in Health, 2019, 22, S832.	0.1	1
165	A biotechnológia hazánkban. Hungarian Statistical Review, 2021, 99, 512-540.	0.0	1
166	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. Musculoskeletal Science and Practice, 2021, 55, 102420.	0.6	1
167	Az egészségügy finanszírozásának fenntarthatósága. Magyar Tudomány, 0, , .	0.0	1
168	PNS38 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Jordan, Lebanon Palestine and Syria 1995-2019. Value in Health, 2020, 23, S650.	0.1	1
169	PNS20 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Egypt 1995-2019. Value in Health, 2020, 23, S647.	0.1	1
170	PNS19 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Algeria, Libya, Morocco and Tunisia 1995-2019. Value in Health, 2020, 23, S647.	0.1	1
171	PNS34 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from the GULF Region 1995-2019. Value in Health, 2020, 23, S649.	0.1	1
172	PHPI8 INTRODUCING THE "FOURTH HURDLE"™ IN THE NEW EUROPEAN UNION MEMBER STATES: THE CASE OF HUNGARY. Value in Health, 2004, 7, 714.	0.1	0
173	PHP17 EFFICIENCY OF RHEUMATOLOGY HOSPITAL CARE: CHANGES IN THE AVERAGE LENGTH OF STAY IN RHEUMATOLOGY DEPARTMENTS IN HUNGARY. Value in Health, 2006, 9, A212-A213.	0.1	0
174	PDB41 EFFECT OF COMPLICATIONS ON HEALTH RELATED QUALITY OF LIFE IN HUNGARIAN INSULIN TREATED DIABETIC PATIENTS. Value in Health, 2006, 9, A237.	0.1	0
175	POS10 OSTEOPOROSIS RELATED HEALTH CARE UTILISATION IN HUNGARY BY THE NATIONWIDE HEALTH INSURANCE DATABASE. Value in Health, 2006, 9, A381.	0.1	0
176	POS15 CHANGES IN THE HEALTH STATUS AFTER FEMORAL NECK FRACTURE MEASURED BY EQ-5D. Value in Health, 2006, 9, A383.	0.1	0
177	PHP37 THE MARKET SHARE OF PRIVATE FOR-PROFIT AND NONPROFIT HEALTH CARE PROVIDERS FROM THE HUNGARIAN HEALTH INSURANCE BUDGET. Value in Health, 2007, 10, A33.	0.1	0
178	PAR24 COST-UTILITY ANALYSIS OF RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS AFTER ANTI-TNF-ALFA THERAPY IN HUNGARY. Value in Health, 2007, 10, A250.	0.1	0
179	PUK9 HEALTH STATUS AND COSTS OF PATIENTS UNDERGOING HAEMODIALYSIS TREATMENT IN HUNGARY. Value in Health, 2007, 10, A315-A316.	0.1	0
180	PUK18 INCREASING MARKET SHARE OF PRIVATE DIALYSIS CENTRES FROM HEALTH INSURANCE EXPENDITURES IN HUNGARY. Value in Health, 2007, 10, A318.	0.1	0

#	ARTICLE	IF	CITATIONS
181	PCN52 GAP BETWEEN TREATMENT COST OF AND MORTALITY DUE TO CERVICAL CANCER IN HUNGARY. Value in Health, 2007, 10, A338.	0.1	0
182	PHP3 BUDGET SILO MENTALITY BEHIND THE FORMER IRON CURTAIN:A CASE STUDY FROM HUNGARY. Value in Health, 2007, 10, A361.	0.1	0
183	POS2 CORRELATION BETWEEN PREDICTORS AND SUBSEQUENT SURGICAL MANAGEMENT FOLLOWING INTERNAL FIXATION OF FEMORAL NECK FRACTURES. Value in Health, 2007, 10, A393-A394.	0.1	0
184	POS3 THE ROLE OF SURGICAL DELAY ON EARLY MORTALITY IN PATIENTS WITH FEMORAL NECK FRACTURE. Value in Health, 2007, 10, A394.	0.1	0
185	PCV16 HEALTH INSURANCE COSTS OF STROKE HOSPITAL TREATMENTS IN HUNGARY; 2003-2005. Value in Health, 2007, 10, A410.	0.1	0
186	PMS71 A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY. Value in Health, 2008, 11, A549-A550.	0.1	0
187	PCN90 EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN UNDER THE AGE OF 25 YEARS. Value in Health, 2008, 11, A81-A82.	0.1	0
188	PCV46 COSTS OF ACUTE MYOCARDIAL INFARCTION IN HUNGARY; 2003-2005. Value in Health, 2008, 11, A200.	0.1	0
189	PMS2 COMPARATIVE EFFICACY OF BIOLOGICAL TREATMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS; SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS. Value in Health, 2008, 11, A254-A255.	0.1	0
190	PMS4 THE EFFECT OF HOSPITAL VOLUME ON 30 DAYS MORTALITY FOLLOWING HIP FRACTURE. Value in Health, 2008, 11, A255.	0.1	0
191	PMS23 MODELLING OF BURDEN OF FEMORAL NECK FRACTURE IN 2007 FROM PURCHASER'S POINT OF VIEW. Value in Health, 2008, 11, A261.	0.1	0
192	PSS2 EFFICACY OF BIOLOGICAL TREATMENT IN PATIENTS WITH PSORIASIS; META-ANALYSIS. Value in Health, 2008, 11, A284-A285.	0.1	0
193	PMS83 COMPARISON OF A GENERIC UTILITY MEASURE (EQ-5D) AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS. Value in Health, 2009, 12, A449.	0.1	0
194	PMS27 COSTS OF PSORIATIC ARTHRITIS IN HUNGARY; RESULTS FROM A CROSS-SECTIONAL SURVEY. Value in Health, 2009, 12, A68.	0.1	0
195	PHP35 THE EFFECT OF THE WITHDRAWAL OF HOSPITAL DAILY FEE ON THE NUMBER OF ADMISSIONS TO ACUTE CARE HOSPITAL WARDS IN HUNGARY. Value in Health, 2009, 12, A85.	0.1	0
196	PMH15 COSTS OF DEMENTIA IN HUNGARY. Value in Health, 2009, 12, A175.	0.1	0
197	PHP82 ASSESSMENT OF LIFESPAN AND HEALTH STATUS EXPECTATIONS IN HUNGARY; RESULTS OF A WEB-SURVEY. Value in Health, 2009, 12, A252.	0.1	0
198	PMH67 QUALITY OF LIFE OF OUTPATIENT DEMENTED PATIENTS IN HUNGARY. Value in Health, 2009, 12, A363.	0.1	0

#	ARTICLE	IF	CITATIONS
199	PMS56 ACCESS TO BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS IN CENTRAL AND EASTERN EUROPEAN (CEE) COUNTRIES. Value in Health, 2010, 13, A133.	0.1	0
200	PCV35 SEASONAL VARIATION AND INFLUENCE OF METEOROLOGICAL FACTORS IN CASE OF ACUTE CEREBROVASCULAR EVENTS. Value in Health, 2010, 13, A155.	0.1	0
201	PND9 ASSESSMENT OF DISEASE BURDEN ASSOCIATED WITH EPILEPSY IN HUNGARY, BASED ON A CROSS-SECTIONAL QUESTIONNAIRE SURVEY OF 100 PATIENTS. Value in Health, 2010, 13, A389.	0.1	0
202	PHP129 ATTITUDES OF HUNGARIAN POPULATION TOWARD CO-PAYMENTS. Value in Health, 2010, 13, A428.	0.1	0
203	PMS56 Subjective Health Expectations of Rheumatoid Arthritis Patients Starting Biological Therapy. Value in Health, 2011, 14, A312-A313.	0.1	0
204	PHP3 Patient Preferences Considering the Choice of Health Care Providers in Hungary – Results From Discrete Choice Experiment. Value in Health, 2011, 14, A333-A334.	0.1	0
205	PND60 Non-Diabetic Peripheral Neuropathic Pain is Underdiagnosed in GP Practices Although it has High Impact on Patients' Health Related Quality of Life. Value in Health, 2012, 15, A556-A557.	0.1	0
206	Health Related Quality of Life of Patients with Bladder Cancer in Hungary. Value in Health, 2013, 16, A635.	0.1	0
207	Health-Related Quality Of Life And Subjective Happiness Of Patients With Benign Prostatic Hyperplasia: First Results Of A Cross-Sectional Survey From Hungary. Value in Health, 2014, 17, A471-A472.	0.1	0
208	Eq-5d Studies In Nervous System Diseases In Eight Central And Eastern European Countries. Value in Health, 2016, 19, A471.	0.1	0
209	A Cost-Effectiveness Analysis of Biosimilar Infliximab (Inflixtra [®]) For The Treatment of Ankylosing Spondylitis In Nine European Countries. Value in Health, 2016, 19, A540.	0.1	0
210	EQ-5D Studies in Diseases of The Circulatory System in Eight Central and Eastern European Countries. Value in Health, 2016, 19, A657-A658.	0.1	0
211	Epidemiology and Survival in Prostate Cancer; A Population Based Study Analysing The Hungarian National Health Insurance Found Database. Value in Health, 2016, 19, A716.	0.1	0
212	Willingness To Pay For Primary Dysmenorrhea Health States. Value in Health, 2016, 19, A404-A405.	0.1	0
213	O17 Is it appropriate to use the Dermatology Life Quality Index for medical-decision making in psoriasis patients?. Journal of Investigative Dermatology, 2016, 136, S163.	0.3	0
214	Measurement Properties of The EQ-5D-5l Compared To The EQ-5D-3L In Psoriasis Patients. Value in Health, 2016, 19, A572-A573.	0.1	0
215	O15 The impact of pemphigus on health-related quality of life: First results with the EQ-5D questionnaire. Journal of Investigative Dermatology, 2017, 137, S195.	0.3	0
216	O17 Women, elderly and less educated psoriasis patients provide more “not relevant” responses on the Dermatology Life Quality Index - is it a problem?. Journal of Investigative Dermatology, 2017, 137, S195.	0.3	0

#	ARTICLE	IF	CITATIONS
217	Estimating Survival After Radical Prostatectomy In Prostate Cancer; A Propensity-Score Matching Method. Value in Health, 2017, 20, A421.	0.1	0
218	Applicability Of The EQ-5D-3L Descriptive System To Explore Subjective Future Health Expectations. Value in Health, 2017, 20, A690.	0.1	0
219	PMU43 - THE COST OF INFORMAL CARE IN HUNGARY: A POOLED ANALYSIS OF 14 CROSS-SECTIONAL STUDIES. Value in Health, 2018, 21, S315.	0.1	0
220	PMU91 - USE OF EQ-5D IN CENTRAL AND EASTERN EUROPE 2000-2015: NEUROLOGICAL DISORDERS. Value in Health, 2018, 21, S323.	0.1	0
221	PMU126 - SUBJECTIVE EXPECTATIONS REGARDING FUTURE HEALTH, WELL-BEING AND HEALTHCARE COSTS IN HUNGARY. Value in Health, 2018, 21, S328.	0.1	0
222	PMS119 - ACCEPTABILITY OF HEALTH PROBLEMS IN CHRONIC MUSCULOSKELETAL DISEASES. Value in Health, 2018, 21, S308.	0.1	0
223	PSS60 - UTILITY ASSESSMENT FOR PEMPHIGUS HEALTH STATES USING VISUAL ANALOGUE SCALE AND TIME TRADE-OFF METHODS. Value in Health, 2018, 21, S433.	0.1	0
224	PRM185 - COMPARISON OF THE MEASUREMENT PROPERTIES OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS WITH CROHNâ€™S DISEASE. Value in Health, 2018, 21, S388.	0.1	0
225	PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHNâ€™S DISEASE. Value in Health, 2018, 21, S150.	0.1	0
226	PRM171 - DETERMINANTS OF THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES: EXPLORING A NEW APPLICATION OF THE EQ VAS. Value in Health, 2018, 21, S385.	0.1	0
227	PMU124 - DOES THE CHOICE OF EQ-5D-3L TARIFF MATTER FOR THE EVALUATION OF CHRONIC DISEASES? COMPARATIVE ANALYSIS OF THE POLISH, UK, SLOVENIAN AND EUROPEAN SCORES. Value in Health, 2018, 21, S328.	0.1	0
228	é“¶â±ç—...ä-DLQI æ—°è„â^†â...-â¼çš„æè®. British Journal of Dermatology, 2018, 179, e217-e217.	1.4	0
229	EQâ€5D âœ”â©ç—±ç—®äçš„æ^â° . British Journal of Dermatology, 2019, 180, e126.	1.4	0
230	176 Measuring quality of life with the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. Journal of Investigative Dermatology, 2019, 139, S244.	0.3	0
231	Validity of the EQâ€5D in pemphigus. British Journal of Dermatology, 2019, 180, e110.	1.4	0
232	PMU131 VALIDITY OF THE POLISH VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE POLISH GENERAL POPULATION. Value in Health, 2019, 22, S731.	0.1	0
233	PMU139 VALIDITY OF THE SLOVENIAN VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE SLOVENIAN GENERAL POPULATION. Value in Health, 2019, 22, S733.	0.1	0
234	PNS399 DEVELOPMENT OF POPULATION TARIFFS FOR THE CARER-QOL-7D INSTRUMENT FOR HUNGARY, POLAND AND SLOVENIA: A DISCRETE CHOICE EXPERIMENT STUDY TO MEASURE THE BURDEN OF INFORMAL CAREGIVING. Value in Health, 2019, 22, S833.	0.1	0

#	ARTICLE	IF	CITATIONS
235	PNS393 POPULATION NORMS WITH THE ICECAP-A AND ICECAP-O CAPABILITY MEASURES IN HUNGARY. Value in Health, 2019, 22, S831-S832.	0.1	0
236	PNS398 THE ASSOCIATION BETWEEN EHEALTH-LITERACY, SHARED DECISION-MAKING AND HEALTH RISK BEHAVIOURS IN AN ONLINE SAMPLE OF THE HUNGARIAN GENERAL POPULATION. Value in Health, 2019, 22, S832-S833.	0.1	0
237	PNS379 SUFFERING ALONE: UNMET NEEDS FOR INFORMAL CARE IN HUNGARY, POLAND AND SLOVENIA. Value in Health, 2019, 22, S829.	0.1	0
238	PNS389 VALIDITY OF THE HUNGARIAN TRANSLATION OF THE CARERQOL-7D INSTRUMENT AMONG INFORMAL CAREGIVERS IN THE HUNGARIAN GENERAL POPULATION. Value in Health, 2019, 22, S830-S831.	0.1	0
239	PMS1 MUSCULOSKELETAL HEALTH AND CAPABILITY OF WELL-BEING MEASURED BY THE ICECAP-A AND -ICECAP-O INSTRUMENTS. Value in Health, 2020, 23, S214.	0.1	0
240	PNS203 ICECAP-A AND ICECAP-O CAPABILITY OF WELL-BEING MEASURES: WHICH ONE TO USE IN AGE-GROUP 50-70?. Value in Health, 2020, 23, S321.	0.1	0
241	PMU10 A SCOPING REVIEW OF HEALTH ECONOMIC EVALUATIONS FROM THE MIDDLE EAST AND NORTH AFRICA REGION. Value in Health, 2020, 23, S234-S235.	0.1	0
242	PGI21 COST PER ACCEPTABLE LIFE-YEARS AND COST PER QALY GAINS IN NON-ACCEPTABLE HEALTH STATE FOR BIOLOGICAL TREATMENT IN CROHN'S DISEASE, A NOVEL APPROACH IN HEALTH ECONOMIC MODELLING. Value in Health, 2020, 23, S146.	0.1	0
243	A magÄĳfinanszÄĳrozÄĳjs helye a magyar egÄĳszsÄĳgÄĳ1/4gyben; ForrÄĳshiÄĳnyban az egÄĳszsÄĳgÄĳ1/4gy â€œ Mit tehetnek a biztosÄĳtÄĳk?. BiztosÄĳtÄĳs Äĳs KockÄĳzat, 2016, 3, .	0.1	0
244	Long-term care financing in Europe: An overview. Zdrowie Publiczne I ZarzÄĳdzanie, 2019, 17, 131-145.	0.3	0
245	A biolÄĳgiai terÄĳpia egÄĳszsÄĳggazdasÄĳgi vonatkozÄĳsai. Magyar TudomÄĳny, 0, , .	0.0	0
246	PNS251 Psychometric Properties of the Hungarian Language Version of the 13-ITEM Patient Activation Measure (PAM-13) in an Online Sample of the Adult General Population. Value in Health, 2020, 23, S683.	0.1	0
247	PMS6 Validation of the Musculoskeletal Health Questionnaire (MSK-HQ) for Hungary: Results of an Online CROSS-Sectional Survey Among the General Population. Value in Health, 2020, 23, S593.	0.1	0
248	PNS24 Standardized Unit Cost Calculation for Informal Care Time and CROSS-Country Comparison: PECUNIA Project. Value in Health, 2020, 23, S647-S648.	0.1	0
249	PNS53 Population Normative DATA for the Health Assessment Questionnaire Disability INDEX in Hungary. Value in Health, 2020, 23, S652.	0.1	0
250	POSC286 Methodological Quality and Transferability of Cancer Costs within the MENA Region: A Systematic Review and Secondary Analysis of Published Data. Value in Health, 2022, 25, S190.	0.1	0
251	Quality assurance in Hungarian hospitals: a new focus for management development. The Journal of Health Administration Education, 1994, 12, 551-8.	0.5	0
252	Title is missing!. , 2020, 15, e0235165.		0

#	ARTICLE	IF	CITATIONS
253	Title is missing!. , 2020, 15, e0235165.		0
254	Title is missing!. , 2020, 15, e0235165.		0
255	Title is missing!. , 2020, 15, e0235165.		0
256	Title is missing!. , 2020, 15, e0235165.		0
257	Title is missing!. , 2020, 15, e0235165.		0
258	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
259	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
260	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
261	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0